Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Combination Therapy
100%
Large Hospital
100%
Infectious Disease Specialist
100%
Antibiotic Treatment
100%
Infection Treatment
100%
ESCMID
100%
Carbapenem-resistant Gram-negative Bacilli
100%
Polymyxin
50%
Pseudomonas Aeruginosa (P. aeruginosa)
33%
Multidrug-resistant Gram-negative Bacteria
33%
Aminoglycosides
33%
Carbapenem
33%
Israel
16%
Treatment Strategy
16%
Tertiary Care
16%
Monotherapy
16%
Spain
16%
Italy
16%
Greece
16%
Web-based
16%
France
16%
Bacteremia
16%
Treatment Efficacy
16%
Questionnaire Survey
16%
Pneumonia
16%
Central Nervous System Infections
16%
Carbapenem-resistant Enterobacteriaceae
16%
Overall Response Rate
16%
Specific Rate
16%
Acute Hospital
16%
Resistance Development
16%
Rifampicin
16%
University-affiliated
16%
Enterobacteriaceae
16%
Hospital Beds
16%
Slovenia
16%
Acinetobacter Baumannii (A. baumannii)
16%
Baumannii
16%
Infection Management
16%
Tigecycline
16%
Fosfomycin
16%
Goal Intention
16%
Kosovo
16%
Closed End
16%
Preferred Treatment
16%
Recurrent Urinary Tract Infections (rUTI)
16%
Antibiotic Management
16%
Medicine and Dentistry
Antibiotic Therapy
100%
Infection
100%
Cross Sectional Study
100%
Combination Therapy
100%
Gram-Negative Bacteria
100%
Infectious Disease
100%
Carbapenem
100%
Polymyxin
50%
Pseudomonas aeruginosa
33%
Aminoglycoside
33%
Urinary Tract Infection
16%
Monotherapy
16%
Tertiary Care
16%
Emergency Care
16%
Carbapenem-Resistant Enterobacteriaceae
16%
Bloodstream Infection
16%
Rifampicin
16%
Central Nervous System Infection
16%
Acinetobacter Baumannii
16%
Enterobacteriaceae
16%
Fosfomycin
16%
Tigecycline
16%
Antimicrobial Agent
16%
Pneumonia
16%
Pharmacology, Toxicology and Pharmaceutical Science
Combination Therapy
100%
Infection
100%
Cross Sectional Study
100%
Gram Negative Bacterium
100%
Carbapenem
100%
Antimicrobial Agent
100%
Diseases
100%
Polymyxin
50%
Pseudomonas aeruginosa
33%
Aminoglycoside
33%
Monotherapy
16%
Urinary Tract Infection
16%
Rifampicin
16%
Central Nervous System Infection
16%
Bloodstream Infection
16%
Enterobacteriaceae
16%
Acinetobacter Baumannii
16%
Carbapenem Resistant Enterobacteriaceae
16%
Tigecycline
16%
Fosfomycin
16%
Pneumonia
16%
Nursing and Health Professions
Infection
100%
Combination Therapy
100%
Infectious Disease Specialist
100%
Antibiotic Therapy
100%
Carbapenem
100%
Cross-Sectional Survey
100%
Polymyxin
50%
Aminoglycoside
33%
Emergency Care
16%
Monotherapy
16%
Urinary Tract Infection
16%
Bloodstream Infection
16%
Tertiary Health Care
16%
Rifampicin
16%
Central Nervous System Infection
16%
Carbapenem Resistant Enterobacteriaceae
16%
Antimicrobial Agent
16%
Pneumonia
16%
Tigecycline
16%
Fosfomycin
16%
Immunology and Microbiology
Gram-Negative Bacteria
100%
Infectious Disease
100%
Antimicrobial Agent
100%
Infection
100%
Polymyxin
50%
Pseudomonas aeruginosa
33%
Central Nervous System
16%
Urinary Tract
16%
Carbapenem Resistant Enterobacteriaceae
16%
Enterobacteriaceae
16%
Acinetobacter Baumannii
16%